175 related articles for article (PubMed ID: 1017154)
1. Pharmacokinetics and effects of propranolol in terminal uraemic patients and in patients undergoing regular dialysis treatment.
Bianchetti G; Graziani G; Brancaccio D; Morganti A; Leonetti G; Manfrin M; Sega R; Gomeni R; Ponticelli C; Morselli PL
Clin Pharmacokinet; 1976; 1(5):373-84. PubMed ID: 1017154
[TBL] [Abstract][Full Text] [Related]
2. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
3. Effect of dose and uremia on plasma and urine profiles of propranolol metabolites.
Schneck DW; Pritchard JF; Gibson TP; Vary JE; Hayes AH
Clin Pharmacol Ther; 1980 Jun; 27(6):744-55. PubMed ID: 7379441
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of recombinant hirudin in hemodialyzed end-stage renal failure patients.
Vanholder R; Camez A; Veys N; Van Loo A; Dhondt AM; Ringoir S
Thromb Haemost; 1997 Apr; 77(4):650-5. PubMed ID: 9134637
[TBL] [Abstract][Full Text] [Related]
5. Reduced extraction of I-propranolol by perfused rat liver in the presence of uremic blood.
Terao N; Shen DD
J Pharmacol Exp Ther; 1985 May; 233(2):277-84. PubMed ID: 3999018
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of oral propranolol in chronic renal disease.
Lowenthal DT; Briggs WA; Gibson TP; Nelson H; Cirksena WJ
Clin Pharmacol Ther; 1974 Nov; 16(5 Part 1):761-9. PubMed ID: 4426144
[No Abstract] [Full Text] [Related]
7. Propranolol in hypertensive dialysis patients: efficacy and compliance.
Briggs WA; Lowenthal DT; Cirksena WJ; Price WE; Gibson TP; Flamenbaum W
Clin Pharmacol Ther; 1975 Nov; 18(5 Pt 1):606-12. PubMed ID: 1183140
[TBL] [Abstract][Full Text] [Related]
8. Propranolol disposition in renal failure.
Wood AJ; Vestal RE; Spannuth CL; Stone WJ; Wilkinson GR; Shand DG
Br J Clin Pharmacol; 1980 Dec; 10(6):561-6. PubMed ID: 7470370
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of propranolol: a review.
Shand DG
Postgrad Med J; 1976; 52 Suppl 4():22-25. PubMed ID: 787953
[TBL] [Abstract][Full Text] [Related]
10. Kinetics and cardiac effects of propranolol in humans.
Ochs HR; Grube E; Greenblatt DJ; Knüchel M; Bodem G
Klin Wochenschr; 1982 May; 60(10):521-5. PubMed ID: 7098380
[TBL] [Abstract][Full Text] [Related]
11. Chronic hemodynamic effects of propranolol treatment in dialysis-refractory hypertension.
Maggiore Q; Zoccali C; Monzani G; Contini C
Nephron; 1978; 22(4-6):391-8. PubMed ID: 740103
[TBL] [Abstract][Full Text] [Related]
12. Prevention of clot formation during haemodialysis using the direct thrombin inhibitor melagatran in patients with chronic uraemia.
Attman PO; Ottosson P; Samuelsson O; Eriksson UG; Eriksson-Lepkowska M; Fager G
Nephrol Dial Transplant; 2005 Sep; 20(9):1889-97. PubMed ID: 15928099
[TBL] [Abstract][Full Text] [Related]
13. Plasma and Lp(a)-associated PAF-acetylhydrolase activity in uremic patients undergoing different dialysis procedures.
Milionis HJ; Elisaf MS; Karabina SA; Bairaktari E; Tselepis AD; Siamopoulos KC
Kidney Int; 1999 Dec; 56(6):2276-85. PubMed ID: 10594806
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and dialysability of naltrexone in patients undergoing hemodialysis.
Kambia NK; Dine T; Odou P; Bah S; Azar R; Gressier B; Dupin-Spriet T; Luyckx M; Brunet C
Eur J Drug Metab Pharmacokinet; 2004; 29(4):225-30. PubMed ID: 15726882
[TBL] [Abstract][Full Text] [Related]
15. Clinical pharmacokinetics and pharmacological actions of a long-acting formulation of propranolol.
Ohashi K; Ebihara A; Kondo K; Usami M
Arzneimittelforschung; 1984; 34(4):507-12. PubMed ID: 6378211
[TBL] [Abstract][Full Text] [Related]
16. Differential effect of chronic renal failure on the pharmacokinetics of lidocaine in patients receiving and not receiving hemodialysis.
De Martin S; Orlando R; Bertoli M; Pegoraro P; Palatini P
Clin Pharmacol Ther; 2006 Dec; 80(6):597-606. PubMed ID: 17178261
[TBL] [Abstract][Full Text] [Related]
17. Analysis and disposition of low dose oral propranolol.
MacKichan JJ; Pyszczynski DR; Jusko WJ
Res Commun Chem Pathol Pharmacol; 1978 Jun; 20(3):531-8. PubMed ID: 674830
[TBL] [Abstract][Full Text] [Related]
18. Blood levels of long-acting propranolol in normal subjects and patients with renal failure.
Kawasaki T; Ueno M; Uezono K; Abe I; Kawazoe N; Omae T; Nakamura S; Cooper RG; Stafford LE
Fukuoka Igaku Zasshi; 1983 Nov; 74(11):737-43. PubMed ID: 6676140
[No Abstract] [Full Text] [Related]
19. Pharmacokinetics of ritanserin in patients undergoing hemodialysis.
Zazgornik J; Kuska J; Kokot F; Koch S; Van Peer A; Huang ML; Heykants J
J Clin Pharmacol; 1991 Jul; 31(7):657-61. PubMed ID: 1910052
[TBL] [Abstract][Full Text] [Related]
20. Plasma noradrenaline and blood pressure in uremia.
Zuccalà A; Chiarini C; Degli Esposti E; Gaggi R; Santoro A; Sturani A; Zucchelli P
J Clin Hypertens; 1985 Jun; 1(2):161-9. PubMed ID: 3915321
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
